Basit öğe kaydını göster

dc.contributor.authorORHAN, OKAN
dc.contributor.authorKilciksiz, Sevil
dc.contributor.authorCelik, Omur Karakoyun
dc.contributor.authorPAK, YÜCEL
dc.contributor.authorDEMİRAL, AYŞE NUR
dc.contributor.authorPehilvan, Mustafa
dc.contributor.authorHaydaroglu, Ayfer
dc.contributor.authorAgaoglu, Fulya
dc.contributor.authorTokatli, Fusun
dc.contributor.authorZincircioglu, Burhanedtin
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorOzseker, Naciye
dc.contributor.authorYersal, Ozlem
dc.contributor.authorNiang, Umar
dc.date.accessioned2021-03-05T20:04:20Z
dc.date.available2021-03-05T20:04:20Z
dc.date.issued2008
dc.identifier.citationKilciksiz S., Celik O. K. , PAK Y., DEMİRAL A. N. , Pehilvan M., ORHAN O., Tokatli F., Agaoglu F., Zincircioglu B., ATASOY B. M. , et al., "Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party", AMERICAN JOURNAL OF HEMATOLOGY, cilt.83, ss.702-707, 2008
dc.identifier.issn0361-8609
dc.identifier.othervv_1032021
dc.identifier.otherav_d244405b-96fd-443d-bd68-39bb73ad9f15
dc.identifier.urihttp://hdl.handle.net/20.500.12627/138924
dc.identifier.urihttps://doi.org/10.1002/ajh.21211
dc.description.abstractTo identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (FIT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (FIT) alone while 38 of them (47.5%) were treated with surgery (S) and FIT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of >= 50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at >= 50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectHEMATOLOJİ
dc.titleClinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party
dc.typeMakale
dc.relation.journalAMERICAN JOURNAL OF HEMATOLOGY
dc.contributor.departmentGaziantep Üniversitesi , ,
dc.identifier.volume83
dc.identifier.issue9
dc.identifier.startpage702
dc.identifier.endpage707
dc.contributor.firstauthorID189593


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster